STAAR Surgical Company $STAA is Defender Capital LLC.’s 9th Largest Position

Defender Capital LLC. reduced its stake in STAAR Surgical Company (NASDAQ:STAA) by 33.1% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 431,187 shares of the medical instruments supplier’s stock after selling 213,355 shares during the quarter. STAAR Surgical comprises approximately 4.0% of Defender Capital LLC.’s holdings, making the stock its 9th largest position. Defender Capital LLC.’s holdings in STAAR Surgical were worth $12,371,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd boosted its holdings in STAAR Surgical by 2,605.1% in the third quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 1,016 shares in the last quarter. Ascentis Independent Advisors bought a new position in shares of STAAR Surgical during the first quarter valued at $77,000. Tower Research Capital LLC TRC increased its holdings in shares of STAAR Surgical by 375.0% during the second quarter. Tower Research Capital LLC TRC now owns 5,919 shares of the medical instruments supplier’s stock valued at $99,000 after acquiring an additional 4,673 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of STAAR Surgical by 9,928.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,513 shares of the medical instruments supplier’s stock worth $121,000 after purchasing an additional 4,468 shares during the last quarter. Finally, Fifth Third Bancorp raised its position in shares of STAAR Surgical by 2,867.1% in the 1st quarter. Fifth Third Bancorp now owns 11,008 shares of the medical instruments supplier’s stock worth $206,000 after purchasing an additional 10,637 shares during the last quarter. Hedge funds and other institutional investors own 96.70% of the company’s stock.

STAAR Surgical Price Performance

NASDAQ STAA opened at $25.12 on Tuesday. STAAR Surgical Company has a one year low of $15.59 and a one year high of $35.87. The stock has a 50-day moving average of $27.11 and a 200 day moving average of $24.01. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -58.42 and a beta of 1.26. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.31 and a current ratio of 5.12.

STAAR Surgical (NASDAQ:STAA) last posted its earnings results on Wednesday, May 13th. The medical instruments supplier reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.05. The business had revenue of $93.52 million for the quarter, compared to analysts’ expectations of $78.72 million. STAAR Surgical had a negative net margin of 7.24% and a positive return on equity of 3.31%. The business’s revenue for the quarter was up 119.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.10) EPS. On average, sell-side analysts forecast that STAAR Surgical Company will post 0.13 EPS for the current year.

Wall Street Analysts Forecast Growth

STAA has been the topic of a number of analyst reports. Stifel Nicolaus upped their price target on shares of STAAR Surgical from $18.00 to $31.00 and gave the stock a “hold” rating in a research note on Thursday, May 14th. Wells Fargo & Company raised their price objective on shares of STAAR Surgical from $16.00 to $25.00 and gave the company an “equal weight” rating in a research note on Friday, May 15th. Zacks Research upgraded shares of STAAR Surgical from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 4th. Mizuho increased their price target on shares of STAAR Surgical from $22.00 to $27.00 and gave the company a “neutral” rating in a report on Thursday, May 14th. Finally, Wall Street Zen downgraded shares of STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, six have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, STAAR Surgical presently has an average rating of “Hold” and an average price target of $26.94.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.